fashion -WSS

fashion

author：leisure time 2025-09-28 00:52:06 - browse：547

Christine Kao/STAT

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies.

PBMs, the middlemen of drug pricing negotiations, also claim portions of those lucrative rebates for themselves. So when new market developments threaten to diminish or wipe away that revenue stream, PBMs find crafty ways to keep as much of those dollars as possible — often at the expense of employers.

One such case occurred last year, when a wave of Humira biosimilars entered the market and drug companies slashed the list prices of their insulin products. CVS Caremark, the PBM owned by CVS Health that oversees the prescription drug benefits of 103 million people, told its employer clients that it anticipated “more lower-cost products (including specialty biosimilars) may become preferred products” on its lists of approved drugs for 2024, according to documents obtained by STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Readout LOUD podcast, live from the STAT Breakthrough Summit East

entertainment

focus

knowledge

WSS

STAT Report: Patient voices and perspectives

Pregnancy ages women, but effects reverse after delivery

What causes rare myocarditis in young men after Covid vaccines?

Dems pitch expanding Medicare power to negotiate drug prices

Search called off for baby washed away in Pennsylvania flash flood

'Patient friction coefficient' can gauge a clinical trial's patient burden

leisure time

fashion

knowledge

What does generative AI mean for health care? We asked experts

Rise in cancer among younger people worries and puzzles doctors

New air purifier tech could be key to improving indoor air quality

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

BioMarin wins approval for gene therapy to treat hemophilia A

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

What does generative AI mean for health care? We asked experts

A new crop of companies is reshaping the health data economy

Novavax promises a turnaround & Lilly roils the obesity market

New Alzheimer's drugs heat up race for early detection blood tests

explore

U.K. officials, researchers try to ease path for bespoke genetic treatments

'Investigate these claims': UFO transparency at center of House hearing

Device maker Teleflex to acquire urology company for $600M

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

New lawsuit accuses health insurer Cigna of denying claims in bulk

entertainment

focus

knowledge

Wikipedia